NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2016
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TROXYCA ER is an extended-release oral capsule combining naltrexone hydrochloride (an opioid antagonist) with oxycodone hydrochloride (an opioid agonist), designed to reduce abuse potential while providing analgesia. It is indicated for moderate to severe chronic pain requiring continuous opioid therapy. The dual mechanism aims to deter misuse by precipitating withdrawal if the capsule is tampered with or taken in excess.
LOE Approaching1.6 years to LOE
Product is within 1.6 years of LOE with moderate competitive pressure (15 competitors), signaling declining team investment and consolidation of brand resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on TROXYCA ER at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.